Aethlon Medical INC: management transactions · United States · SEC (Form 4)

About Aethlon Medical INC

Aethlon Medical, Inc. (ticker: AEMD) is a U.S.-based medical device and clinical-stage therapeutics company listed on the Nasdaq Capital Market in the United States. Headquartered in San Diego, California, Aethlon is focused on advancing its proprietary Hemopurifier® platform, an extracorporeal blood purification device designed to remove circulating pathogenic targets. The company’s corporate roots date back to a reorganization completed on March 10, 1999, and its modern strategy has centered on a lectin-based capture technology that it continues to develop through clinical and preclinical programs. ([aethlonmedical.com](https://www.aethlonmedical.com/investors/sec-filings/all-sec-filings/content/0001683168-19-003996/0001683168-19-003996.pdf)) Aethlon’s business model is built around a single core technology with multiple potential therapeutic applications rather than a broad commercial product portfolio. The Hemopurifier is described by the company as a first-in-class, clinical-stage immunotherapeutic device intended to reduce tumor-derived extracellular vesicles and enveloped viruses in circulation. In oncology, the company is targeting patients with advanced or metastatic solid tumors, particularly those who are unresponsive to or intolerant of standard-of-care therapy. In infectious disease, the Hemopurifier is being evaluated for life-threatening viral infections, and the company has also highlighted potential use cases in organ transplantation. This “pipeline within a single device” approach gives Aethlon broad scientific optionality, but also means that value creation depends heavily on clinical validation, regulatory progress, and eventual commercialization. ([aethlonmedical.com](https://www.aethlonmedical.com/news-media/press-releases/detail/505/aethlon-medical-announces-financial-results-for-the-fiscal)) From a competitive standpoint, Aethlon occupies a highly specialized niche within medtech and biotech. It does not compete as a scaled manufacturer of commoditized devices; instead, it competes in a frontier area at the intersection of blood purification, immunotherapy, and infectious disease treatment. Its differentiation lies in its proprietary lectin resin technology and in the possibility that one platform could address multiple high-unmet-need indications. The flip side is meaningful execution risk: the company remains dependent on clinical data, regulatory approvals, and ongoing capital access, which is typical for a small-cap development-stage healthcare company. Investors should therefore view Aethlon as an early-stage platform story rather than a mature revenue-generating medtech franchise. ([aethlonmedical.com](https://www.aethlonmedical.com/investors/sec-filings/all-sec-filings/content/0001683168-26-000959/aethlon_ex9901.htm)) Recent developments underscore both progress and ongoing development-stage risk. In fiscal 2025, Aethlon reported that the first three patients were treated in its Australian cancer trial, while it also continued research collaborations and technology development work. In September 2025, the company announced issuance of Hemopurifier patents related to Long COVID and COVID-19-associated coagulopathy, strengthening its intellectual-property position. In March 2026, Aethlon said it had engaged Maxim Group LLC to evaluate strategic opportunities, signaling that management is assessing broader corporate alternatives. The company has also repeatedly emphasized cost discipline, cash management, and Nasdaq compliance as important priorities. ([aethlonmedical.com](https://www.aethlonmedical.com/news-media/press-releases/detail/505/aethlon-medical-announces-financial-results-for-the-fiscal))